Results 21 to 30 of about 12,561 (177)

Edoxaban [PDF]

Reactions Weekly, 2018
Ein weiteres «direktes» orales Antikoagulans, das weniger Blutungen verursacht als Warfarin. In welchem Ausmass sich die Studienresultate auf einen Vergleich mit dem in der Schweiz gebräuchlichen Phenprocoumon extrapolieren lassen, ist nicht klar.
Lenka Špinarová, Jindřich Špinar, Růžena Lábrová   +2 more
  +7 more sources

Renal Function and 4-Year Outcomes in Edoxaban-Treated Patients: A Sub-Analysis From the ETNA-AF Europe Study. [PDF]

Eur J Clin Invest
The ETNA‐AF‐Europe 4‐year follow‐up sub‐analysis reaffirms the effectiveness and safety of adherent label‐recommended doses of edoxaban in patients with AF with varying degrees of renal impairment. Low number of patients and events of ¶stroke (n = 2) and †ICH (n = 1) may warrant results to be interpreted with caution.
De Caterina R, Fronk EM, Nunes J, Lamparter M, Kirchhof P, Zoccali C, ETNA‐AF Europe Investigators.   +6 more
europepmc   +2 more sources

Edoxaban [PDF]

Hospital Pharmacy, 2015
Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing ...
Dennis J, Cada, Danial E, Baker, Kyle, Ingram   +2 more
openaire   +3 more sources

Edoxaban dosing patterns in real life practice – Results from the DRESDEN NOAC REGISTRY

Thrombosis Update, 2021
Edoxaban is a non-vitamin K dependent oral anticoagulant (NOAC) licensed for venous thromboembolism treatment or stroke prevention in atrial fibrillation.
Jan Beyer-Westendorf, Sandra Marten, Christiane Naue, Christina Köhler, Luise Tittl, Martin Bornhäuser   +5 more
doaj   +1 more source

Edoxaban Dosing Time Affects Blood Coagulation Inhibition in Rats

TH Open, 2021
Coagulation–fibrinolytic system activity shows daily rhythmicity, with hypercoagulability in the morning and hypocoagulability in the evening. Consequently, the efficacy of anticoagulants may be influenced by their dosing time.
Naoto Nagata, Muneo Kawasumi, Akio Fujimura, Hitoshi Ando   +3 more
doaj   +1 more source

Effects of concomitant use of prasugrel with edoxaban on bleeding time, pharmacodynamics, and pharmacokinetics of edoxaban in healthy elderly Japanese male subjects: a clinical pharmacology study

Thrombosis Journal, 2020
Background Dual therapy with a direct oral anticoagulant (DOAC) plus a P2Y12 receptor inhibitor is recommended in patients with nonvalvular atrial fibrillation who undergo percutaneous coronary intervention.
Ippei Ikushima, Takaaki Akasaka, Yoshiyuki Morishima, Atsushi Takita, Tomoko Motohashi, Tetsuya Kimura   +5 more
doaj   +1 more source

Point-of-care testing for emergency assessment of coagulation in patients treated with direct oral anticoagulants including edoxaban

Neurological Research and Practice, 2021
Background Direct oral anticoagulants (DOAC) including edoxaban are increasingly used for stroke prevention in atrial fibrillation. Despite treatment, annual stroke rate in these patients remains 1–2%.
Florian Härtig, Ingvild Birschmann, Andreas Peter, Sebastian Hörber, Matthias Ebner, Matthias Sonnleitner, Charlotte Spencer, Paula Bombach, Maria-Ioanna Stefanou, Johannes Tünnerhoff, Annerose Mengel, Joachim Kuhn, Ulf Ziemann, Sven Poli   +13 more
doaj   +1 more source

Anticoagulant Treatment Adherence and Persistence in German Patients with Atrial Fibrillation

Cardiology and Therapy, 2023
Introduction Treatment adherence and persistence impact the effectiveness of edoxaban for the prevention of thromboembolism in patients with atrial fibrillation (AF).
Giuseppe Patti, Rosa Wang, Xiaocong Li Marston, Yu-Chen Yeh, Lisa Zimmermann, Xin Ye, Xin Gao, Bernd Brüggenjürgen   +7 more
doaj   +1 more source

Determination of Anti-Xa Inhibitor Plasma Concentrations Using a Universal Edoxaban Calibrator [PDF]

, 2023
A universal calibrator for the determination of all anti-Xa inhibitors would support laboratory processes. We aimed to test the clinical performance of an anti-Xa assay utilizing a universal edoxaban calibrator to determine clinically relevant ...
Gerber, B., Cédric Bovet, Burger, A., Mendez, Adriana, Mendez, A., Walter A. Wuillemin, Adriana Mendez, Wuillemin, W.A., Studt, J.D., Binder, Nikolaus B, Thomas Sauter, Michael Nagler, Studt, Jan-Dirk, Alberio, Lorenzo, Alberio, L., Schmidt, Adrian, Lorenzo Alberio, Annika Burger, Bovet, C., Adrian Schmidt, Nikolaus Binder, Schmidt, A., Nagler, M., Pierre Fontana, Graf, Lukas, Lukas Graf, Burger, Annika, Bernhard Gerber, Gerber, Bernhard, Sauter, Thomas C, Thomas C. Sauter, Graf, L., Binder, N.B., Nikolaus B. Binder, Jan-Dirk Studt, Fontana, P., Nagler, Michael, Sauter, T.C., Fontana, Pierre, Bovet, Cédric, Wuillemin, Walter A, Walter Wuillemin, Schmidt, Adrian; https://orcid.org/, Nagler, Michael; https://orcid.org/, Alberio, Lorenzo; https://orcid.org/, Fontana, Pierre; https://orcid.org/, Gerber, Bernhard; https://orcid.org/   +46 more
core   +2 more sources

Edoxaban [PDF]

Reactions Weekly, 2021
Kirsten Mitchell, Andrea Llano
  +7 more sources